Last reviewed · How we verify
Tapentadol Prolonged Release
Tapentadol is a mu-opioid receptor agonist and noradrenaline reuptake inhibitor that provides analgesia through dual mechanisms.
Tapentadol prolonged release, developed by Grünenthal GmbH, is an opioid analgesic for moderate to severe chronic pain. It has completed several Phase 3 and 4 trials, demonstrating efficacy and safety in various pain conditions, including osteoarthritis and low back pain. The drug lacks an FDA label but has been studied extensively in Europe.
At a glance
| Generic name | Tapentadol Prolonged Release |
|---|---|
| Also known as | - Nucynta, - Palexia, Nucynta, Palexia, Nucynta® |
| Sponsor | Grünenthal GmbH |
| Drug class | Mu-opioid receptor agonist and noradrenaline reuptake inhibitor |
| Target | Mu-opioid receptor; noradrenaline transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Tapentadol binds to mu-opioid receptors to produce opioid-mediated pain relief while simultaneously inhibiting the reuptake of noradrenaline, enhancing descending pain inhibitory pathways. The prolonged-release formulation provides sustained analgesia over 24 hours, allowing for twice-daily dosing. This dual mechanism may offer improved tolerability compared to pure mu-opioid agonists.
Approved indications
- Moderate to severe chronic pain in adults requiring opioid therapy
Common side effects
- Nausea
- Dizziness
- Somnolence
- Constipation
- Vomiting
- Headache
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tapentadol Prolonged Release CI brief — competitive landscape report
- Tapentadol Prolonged Release updates RSS · CI watch RSS
- Grünenthal GmbH portfolio CI